Roivant Sciences Ltd. (ROIV)

NMS – Real vaqt narxi. Valyuta: USD

36.09

+0.84 (2.38%)

Bozor ochiq: Aug 12, 2026, 3:46 PM EDT

35.25

0.00 (0.00%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

08.08.2026

Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon

Roivant Sciences is transitioning from an asset-monetization platform to a commercial-stage biopharma, supported by a strong cash position and imminent product launches. ROIV's $4.7 billion pro forma liquidity eliminates near-term dilution risk, enabling commercialization of brepocitinib and continued pipeline investment without adverse equity market reliance. Brepocitinib's FDA Priority Review for dermatomyositis, with potential approval by September 2026, anchors near-term upside, while label expansions target a >280,000 patient opportunity.

07.08.2026

Roivant Sciences Q1 Earnings Call Highlights

Roivant Sciences NASDAQ: ROIV said it expects a busy second half of 2026, with a potential launch of brepocitinib in dermatomyositis, several clinical readouts and additional regulatory discussions across its pipeline.

06.08.2026

Roivant Sciences Ltd. (ROIV) Q1 2026 Earnings Call Transcript

06.08.2026

Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates

Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.33 per share in line with the Zacks Consensus Estimate.

06.08.2026

Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update

Commercial preparations for brepocitinib in dermatomyositis (DM) are progressing well and on track for launch by the end of September 2026; topline data from Phase 3 study in non-infectious uveitis (NIU) expected in the second half of calendar year 2026 First patients enrolled in the Phase 3 study of brepocitinib in cutaneous sarcoidosis (CS), with topline data expected in calendar year 2028; enrollment in Part 1 of the Phase 2b/3 study in lichen planopilaris (LPP) is progressing well IMVT-1402 proof-of-concept trial in cutaneous lupus erythematosus (CLE) topline data expected in the second half of calendar year 2026; all clinical development timelines remain on track for IMVT-1402 Mosliciguat Phase 2 study in pulmonary hypertension associated with interstitial lung disease (PH-ILD) remains on track, with topline data expected in the second half of calendar year 2026 Genevant and Arbutus received $950 million from Moderna in July 2026 under $2.25 billion settlement, with additional $1.3 billion contingent on favorable resolution of Moderna's § 1498 appeal; filed new international lawsuits against Pfizer and BioNTech covering 21 jurisdictions Roivant reported consolidated cash, cash equivalents, restricted cash and marketable securities of $3.9 billion as of June 30, 2026, excluding the cash payment received from Moderna in July, supporting cash runway into profitability Roivant will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026, to report its financial results for the first quarter ended June 30, 2026, and provide a business update BASEL, Switzerland and LONDON and NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the first quarter ended June 30, 2026, and provided a business update.

06.08.2026

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves' disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis (D2T RA), Sjögren's disease (SjD) and cutaneous lupus erythematosus (CLE) Current cash balance provides runway to the potential launch of IMVT-1402 in GD Roivant will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026 DURHAM, N.C.

06.08.2026

Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)

CS is a highly morbid, chronic, and disfiguring condition with no approved therapies Brepocitinib is the first investigational therapy to generate a positive result in a placebo-controlled CS study (Phase 2 BEACON) and has received FDA Breakthrough Therapy Designation for CS Global Phase 3 study (BEACON+) is underway, evaluating brepocitinib 45 mg once daily against placebo in 140 patients across approximately 70 sites globally; BEACON+ topline data expected in calendar year 2028 Brepocitinib's development program now includes four indications with ongoing or successfully completed registrational trials: dermatomyositis (DM), non-infectious uveitis (NIU), lichen planopilaris (LPP), and CS; potential NDA approval and product launch in DM expected by the end of September 2026 DURHAM, N.C., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Priovant today announced that the first patients have been enrolled in the Phase 3 study evaluating brepocitinib in cutaneous sarcoidosis (CS).

Videolar

No Data

There is no data to display

Press-relizlar

06.08.2026

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

06.08.2026

Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update

06.08.2026

Roivant Sciences Ltd. (ROIV)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Roivant Sciences Ltd. (ROIV)

Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon

Roivant Sciences Q1 Earnings Call Highlights

Roivant Sciences Ltd. (ROIV) Q1 2026 Earnings Call Transcript

Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates

Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)

Videolar

No Data

Press-relizlar

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update

Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)

Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon

Roivant Sciences Q1 Earnings Call Highlights

Roivant Sciences Ltd. (ROIV) Q1 2026 Earnings Call Transcript

Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates

Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)

Videolar

No Data

Press-relizlar

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update

Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)

Search stocks

Roivant Sciences Ltd. (ROIV)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Roivant Sciences Ltd. (ROIV)

Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon

Roivant Sciences Q1 Earnings Call Highlights

Roivant Sciences Ltd. (ROIV) Q1 2026 Earnings Call Transcript

Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates

Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)

Videolar

No Data

Press-relizlar

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update

Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)

Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon

Roivant Sciences Q1 Earnings Call Highlights

Roivant Sciences Ltd. (ROIV) Q1 2026 Earnings Call Transcript

Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates

Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)

Videolar

No Data

Press-relizlar

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update

Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)